313 related articles for article (PubMed ID: 36615138)
1. Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study.
Zhou Y; Fu Q; Shao Z; Zhang K; Qi W; Geng S; Wang W; Cui J; Jiang X; Li R; Zhu Y; Chen S; Shi B
J Clin Med; 2023 Jan; 12(1):. PubMed ID: 36615138
[TBL] [Abstract][Full Text] [Related]
2. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
3. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
4. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
5. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
6. Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer.
Zhou Y; Qi W; Cui J; Zhong M; Lv G; Qu S; Chen S; Li R; Shi B; Zhu Y
Front Oncol; 2022; 12():911725. PubMed ID: 35903679
[TBL] [Abstract][Full Text] [Related]
7. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
8. The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study.
Zhou Y; Fu Q; Shao Z; Qi W; Zhong M; Lv G; Jiang Z; Zhu M; Wang W; Shi B; Chen S; Zhu Y
World J Urol; 2023 Feb; 41(2):455-461. PubMed ID: 36592177
[TBL] [Abstract][Full Text] [Related]
9. Prostate Health Index density aids the diagnosis of prostate cancer detected using magnetic resonance imaging targeted prostate biopsy in Taiwanese multicenter study.
Chang CH; Yu PH; Hsieh PF; Hong JH; Chiang CH; Cheng HM; Wu HC; Huang CY; Lin TP
J Chin Med Assoc; 2024 Jun; ():. PubMed ID: 38829960
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions.
Lee CU; Lee SM; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077710
[TBL] [Abstract][Full Text] [Related]
11. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
12. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
13. Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.
Tao T; Wang C; Liu W; Yuan L; Ge Q; Zhang L; He B; Wang L; Wang L; Xiang C; Wang H; Chen S; Xiao J
Front Oncol; 2021; 11():811866. PubMed ID: 35127526
[TBL] [Abstract][Full Text] [Related]
14. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
15. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
16. Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies.
Wang C; Yuan L; Shen D; Zhang B; Wu B; Zhang P; Xiao J; Tao T
Front Oncol; 2022; 12():1024204. PubMed ID: 36465344
[TBL] [Abstract][Full Text] [Related]
17. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
18. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
19. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI.
Mo LC; Zhang XJ; Zheng HH; Huang XP; Zheng L; Zhou ZR; Wang JJ
Front Oncol; 2022; 12():1068893. PubMed ID: 36523980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]